Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)

@article{Dunbar2007EffectOI,
  title={Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)},
  author={Geoffrey C. Dunbar and Fraser Inglis and Ramana V Kuchibhatla and Tonmoy Sharma and Mark Tomlinson and James K. Wamsley},
  journal={Journal of Psychopharmacology},
  year={2007},
  volume={21},
  pages={171 - 178}
}
Cognitive decline seen in the normal elderly is associated with selective loss of neuronal nicotinic acetylcholine receptors (nAChRs). Nicotine given either by inhalation or transdermally helps cognition, but unacceptable side effects limit its utility. The present study assessed the safety, tolerability and effect on cognition of ispronicline, a highly selective partial agonist at the 4β2 nAChR, in elderly subjects (n =76) with age associated memory impairment (AAMI). This double-blind… 

Figures and Tables from this paper

Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers

TLDR
These early data in healthy subjects provide encouragement to consider development of AZD3480 as a novel agent for the treatment of cognitive decline in the elderly, including age-associated memory impairment and/or dementia of the Alzheimer’s type.

Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.

TLDR
The study did not meet proof of concept criteria: since neither AZD3480 nor donepezil were statistically significantly superior to placebo on ADAS-Cog and was considered to be inconclusive.

The potential of neuronal nicotinic acetylcholine receptor agonists for treating CNS conditions

TLDR
The clinical evidence supporting the potential of new nicotinic acetylcholine receptor (nAChR) agonists for the treatment of CNS conditions is described and discovery strategies for targeting neuronal nAChRs are reviewed as well as some of the opportunities and challenges still ahead.

In vivo Depiction of α7 Nicotinic Receptor Loss for Cognitive Decline in Alzheimer's Disease.

TLDR
The association between Aβ burden and α7-nAChR reduction in the basal forebrain cholinergic system was highlighted in relation to cognitive decline in AD, and suggests that Aβ-linked α7 nA ChR reduction is clinico-pathophyisologically important for considering a good therapeutic target in AD.

Selective α4β2 Nicotinic Acetylcholine Receptor Agonists Target Epigenetic Mechanisms in Cortical GABAergic Neurons

TLDR
The present study suggests that the α4β2 nAChR agonists may be better suited to control the epigenetic alterations of GABAergic neurons in schizophrenia than the α7 nA chR agonist.

A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment

TLDR
It can be concluded the compound likely had a beneficial effect on cognition after all three co-primary outcomes were positive and appeared safe and well tolerated in this study.

subjects with age-associated memory impairment mg TC-1734 ( AZD 3480 ) with placebo , in older A randomized double-blind study comparing 25 and 50

TLDR
It can be concluded the compound likely had a beneficial effect on cognition after all three co-primary outcomes were positive and appeared safe and well tolerated in this study.

Effects of AZD3480, a neuronal nicotinic acetylcholine receptor agonist, and donepezil on dizocilpine-induced attentional impairment in rats

TLDR
Low doses of AZD3480 may provide therapeutic benefit for reversing attentional impairment in patients suffering from cognitive impairment due to glutamatergic dysregulation and likely other attentional disorders.
...

References

SHOWING 1-10 OF 17 REFERENCES

Cognitive enhancement in man with ispronicline, a nicotinic partial agonist

TLDR
In animal models ispronicline potently improved cognitive function and has no detectable effects on muscle or ganglionic nAChRs, indicating a marked CNS over PNS selectivity.

TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects.

TLDR
The bioavailability, pharmacological, pharmacokinetic, and safety profile of TC-1734 provides an example of a safe, potent and efficacious neuronal nicotinic modulator that holds promise for the management of the hallmark symptomatologies observed in dementia.

Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment

TLDR
Chronic transdermal nicotine treatment in AAMI subjects caused a sustained improvement in clinical symptoms and objective computerized tests of attention, which support the further investigation of nicotinic treatment as a promising therapy for AAMI.

Development of nicotinic drug therapy for cognitive disorders.

The value of assessing cognitive function in drug development

  • K. Wesnes
  • Psychology
    Dialogues in clinical neuroscience
  • 2000
TLDR
Evidence is presented from phase 1 to 3 of the nature and quality of the information that can be obtained by applying the Cognitive Drug Research computerized assessment system to ongoing clinical trials.

Nicotinic systems and cognitive function

  • E. Levin
  • Biology, Psychology
    Psychopharmacology
  • 2005
TLDR
Preliminary studies have found that some aspects of the cognitive deficit in Alzheimer's disease can be attenuated by nicotine, and nicotine may prove to be useful therapeutic treatment for this and other types of dementia.

The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers

TLDR
The Ginkgo/ginseng combination was found significantly to improve an Index of Memory Quality, supporting a previous finding with the compound and represents the first substantial demonstration of improvements to the memory of healthy middle-aged volunteers produced by a phytopharmaceutical.